GCINiox trading in line with expectations
Asthma-focussed medical device company said in an update on Wednesday that it continued to perform strongly in the year to date, meeting management expectations.
The AIM-traded firm, which was holding its annual general meeting, noted that it settled returns claims totaling £0.4m in January, related to its discontinued business operations.
As of 30 April, the unaudited cash balance for Niox was £23.7m, up from £19.9m at the end of December 2023, with the company maintaining a debt-free status.
Niox said it would provide a trading update for the six months ending 30 June in mid-July.
At 1240 BST, shares in Niox Group were up 1.1% at 73.4p.
Reporting by Josh White for Sharecast.com.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.